Clinical trial
Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced…
NCT00128102 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00128102 |
|---|---|
| Title | Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) |
| Official title | A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Mesothelioma, Lung Cancer |
| Intervention type | Drug |
| Interventions | Vorinostat, Placebo |
| Enrollment | 661 |
| Start date | Jun 30, 2005 |
| Primary completion | Jul 15, 2011 |
| Completion | Nov 21, 2011 |
| First posted | Aug 9, 2005 |
| Last update posted | Oct 26, 2020 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: